文献速递乳腺癌

在EORTC 10041/BIG 03-04 MINDACT试验入组的临床低危患者中,使用70基因签名对多灶性乳腺癌进行特征分析

Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
PubMed 文献 · Eur J Cancer · 2017-05-03

基于MINDACT试验中临床低危乳腺癌患者,比较单灶与多灶肿瘤(多灶取最大病灶)的70基因签名与无远处转移生存。研究纳入3090例单灶与238例多灶患者,多灶肿瘤更常见高危基因组风险,但肿瘤灶性与5年无远处转移生存无显著关联。

要点

  • 多灶肿瘤的高基因组风险比例高于单灶肿瘤(22.7% vs 17.3%,OR 1.45)。
  • 多灶与单灶肿瘤5年无远处转移生存无显著差异(96.9% vs 97.1%,HR 1.55)。
  • 未观察到70基因签名与肿瘤灶性在无远处转移生存上的交互信号。

核心结论

  • 在临床低危的MINDACT患者中,多灶肿瘤较单灶肿瘤更可能具有高危70基因签名特征;未观察到多灶性与70基因签名在无远处转移生存方面存在显著交互作用。

研究设计与样本

  • 分析EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER 10041/BIG 03-04 MINDACT试验中入组的临床低危乳腺癌患者,临床低危由修改版Adjuvant! Online的10年复发或死亡风险截断值定义。
  • MINDACT入组标准规定,若不同病灶病理特征相似,多灶性疾病患者可入组;多灶性疾病由病例报告表(CRF)中所有浸润性肿瘤灶直径总和的条目推断。
  • 比较单灶与多灶(取最大病灶)患者的临床病理特征与基因表达,并评估多灶性与70基因签名及5年无远处转移生存的关联。

主要发现

  • 研究纳入3090例临床低危单灶患者与238例多灶患者。
  • 除局部病理显示多灶肿瘤中小叶癌比例更高(21.8% vs 10.8%)外,多灶与单灶肿瘤的基线特征未见差异。
  • 多灶肿瘤患者较单灶肿瘤患者更可能为高基因组风险(22.7% vs 17.3%,OR 1.45,95%CI 1.02-2.07,P=0.038)。
  • 未发现肿瘤灶性与无远处转移生存的显著关联(单灶97.1% vs 多灶96.9%,HR=1.55,95%CI 0.68-3.46,P=0.172)。
  • 未观察到70基因签名的预后效应与肿瘤灶性在无远处转移生存方面存在潜在交互作用的信号。

关键数值与推荐

  • 多灶肿瘤高基因组风险22.7% vs 单灶17.3%,OR 1.45,95%CI 1.02-2.07,P=0.038。
  • 5年无远处转移生存:单灶97.1% vs 多灶96.9%,HR=1.55,95%CI 0.68-3.46,P=0.172。
  • 基线小叶癌比例:多灶21.8% vs 单灶10.8%(局部病理)。

临床怎么用

  • 作者结论认为,在临床低危MINDACT患者中多灶肿瘤更可能具有高危70基因签名特征,未观察到多灶性与70基因签名在无远处转移生存上的显著交互作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In multifocal breast cancer, guidelines recommend basing adjuvant systemic treatment decisions on characteristics of the largest lesion, disregarding multifocality as an independent prognosticator. We assessed the association between multifocal disease and both the 70-gene signature (70-GS), and distant metastasis-free survival (DMFS) in clinical low-risk breast cancer patients enrolled in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) trial. PATIENTS AND METHODS: The analysed population consisted of enrolled patients in the MINDACT trial with clinical low-risk disease, defined by a modified Adjuvant! Online cut-off for the 10-year risk of recurrent disease or death. Eligibility criteria of MINDACT dictate that patients with multifocal disease could be included if the different lesions had similar pathological characteristics. The presence of multifocal disease was deducted from the case report form (CRF)-question for sum of diameter for all invasive tumour foci. Clinicopathological characteristics and gene expression of patients with unifocal and multifocal (largest lesion) disease were compared. Subsequently, the association between multifocal disease and the 70-GS was evaluated as well as the association between multifocality and 5-year DMFS. RESULTS: The study included 3090 clinical low-risk patients with unifocal and 238 patients with multifocal disease. Apart from a higher prevalence of lobular tumours (21.8% versus 10.8%, by local pathology), we did not observe differences in baseline characteristics between multifocal and unifocal tumours. Patients with multifocal tumours were more likely to be at high genomic risk as compared to patients with unifocal tumours (22.7% versus 17.3%, odds ratio [OR] 1.45, 95% confidence interval [CI] 1.02-2.07, P = 0.038). We did not find a significant association between tumour focality and DMFS (97.1% for unifocal versus 96.9% for multifocal, hazard ratio [HR] = 1.55, 95% CI 0.68-3.46, P = 0.172), nor a signal for a potential interaction between the prognostic effect of the 70-GS and focality of the tumour regarding DMFS. CONCLUSION: In the group of clinical low-risk MINDACT patients, multifocal tumours were more likely to have a high-risk 70-GS profile compared to unifocal tumours. We did not observe a significant interaction between multifocality and the 70-GS with respect to survival without distant metastasis in these patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Aalders KC, Kuijer A, Straver ME, et al. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. Eur J Cancer. 2017. PMID: 28477490. doi:10.1016/j.ejca.2017.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。